I will just say that I'm always willing to meet with patient groups to talk about their concerns about drug pricing in the country and how we can better ensure that high-cost drugs are available. Many of those patients are patient groups that are supporting family members with rare diseases.
Of course, we do have a rare disease strategy that is under development as well that may be able to take into account some of their concerns. They have had an opportunity to weigh in on the development of the rare disease strategy, as have many other experts. That strategy is very specifically focused on some of those patient groups' concerns around the cost of these extremely expensive drugs for very few people. That needs a separate strategy.